Diagnostics not part of Hoechst spin-off
This article was originally published in Clinica
The diagnostics business of German group Hoechst will not be part of Hoechst Marion Roussel, the pharmaceutical division which may be floated in part or as a whole in 1997. The diagnostics business, Behring Diagnostics, remains part of the chemicals, fibres and agricultural slice of Hoechst.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.